True ADCP for mAb development
ADCP (antibody-dependent cellular phagocytosis) is an immune defence mechanism in which a cell is engulfed by effector cells of the immune system following targeting by an antibody. ADCP activity is mediated through a diverse range of different effector cells including monocytes, macrophages, dendritic cells or neutrophils with antibody Fc binding arising through different classes of Fcγ receptors.
As with ADCC and CDC cytotoxicity, many therapeutic antibodies and antibody-like proteins can harness and direct ADCP activity towards cell types that express the antigen to which they're directed but for a long time, effector function characterisation of biosimilars has almost exclusively focused on the role of ADCC and CDC with little focus on ADCP activity using primary effector cells. This has changed and biosimilar molecules for which effector modality is possible, ADCP characterisation is required towards the end of clinical development.